Ciprofloxacin (monohydrochloride)

Ciprofloxacin (monohydrochloride)

• CAS Number: 93107-08-5
• UNSPSC Description: Ciprofloxacin (Bay-09867) monohydrochloride is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin monohydrochloride induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin monohydrochloride has anti-proliferative activity and induces apoptosis. Ciprofloxacin monohydrochloride is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity[1][2][3][4].
• Target Antigen: Antibiotic; Apoptosis; Bacterial; Mitochondrial Metabolism; Reactive Oxygen Species; Topoisomerase
• Type: Reference compound
• Related Pathways: Anti-infection;Apoptosis;Cell Cycle/DNA Damage;Immunology/Inflammation;Metabolic Enzyme/Protease;NF-κB
• Applications: COVID-19-immunoregulation
• Field of Research: Infection; Cancer
• Assay Protocol: https://www.medchemexpress.com/Ciprofloxacin_hydrochloride.html
• Purity: 99.90
• Solubility: DMSO : 5 mg/mL (ultrasonic)|H2O : 12.5 mg/mL (ultrasonic)
• Smiles: [H]Cl.O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N4CCNCC4)=C3)C1=O)O
• Molecular Weight: 367.808
• References & Citations: [1]Tsai WC, et, al. Ciprofloxacin-mediated cell proliferation inhibition and G2/M cell cycle arrest in rat tendon cells. Arthritis Rheum. 2008 Jun;58(6):1657-63.|[2]Steenbergen J, et, al. In Vitro and In Vivo Activity of Omadacycline against Two Biothreat Pathogens, Bacillus anthracis and Yersinia pestis. Antimicrob Agents Chemother. 2017 Apr 24;61(5):e02434-16.|[3]Hamblin KA, et, al. Inhaled Liposomal Ciprofloxacin Protects against a Lethal Infection in a Murine Model of Pneumonic Plague. Front Microbiol. 2017 Feb 6;8:91.|[4]LeMaire SA, et, al. Effect of Ciprofloxacin on Susceptibility to Aortic Dissection and Rupture in Mice. JAMA Surg. 2018 Sep 1;153(9):e181804.ACS Appl Polym Mater. 2023 Aug 29.|bioRxiv. 2024 Jan 18.|Adv Sci (Weinh). 2020 Jul 21;7(17):2001374.|Anal Chim Acta. 15 June 2022, 340082.|Animal Diseases. 02 November 2021.|Appl Microbiol Biotechnol. 2022 Apr;106(7):2689-2702.|Arab J Chem. 2024 May, 17, 5, 105745.|bioRxiv. 2024 May 10.|bioRxiv. 2024 Nov 06.|Cardiovasc Toxicol. 2024 Aug 13.|Chemosphere. 2019 Jun;225:378-387. |EBioMedicine. 2022 Apr;78:103943.|Front Microbiol. 2022 Feb 16;12:773664.|Genome Biol. 2023 Apr 30;24(1):98.|Int J Antimicrob Agents. 2018 Aug;52(2):269-271.|iScience. 2023 Oct 5.|J Antimicrob Chemother. 2020 Jul 1;75(7):1850-1858.|Microb Pathog. 2024 Apr 27:106666.|Microbiol Spectr. 2022 Apr 25:e0251821.|Microbiol Spectr. 2022 Jan 12;e0099121.|Molecules. 2023 Jun 8, 28(12), 4628.|Nat Cell Biol. 2024 Jul 12.|Nature. 2024 Aug;632(8027):1137-1144.|NPJ Biofilms Microbiomes. 2024 Oct 28;10(1):111.|Orebro University. 2024.|Patent. US20200101105A1.|Research Square Preprint. 2020 Jun.|Vet Microbiol. 2024 May, 292, 110046.|Virulence. 2024 Oct 10:2415952.|Water Res. 2023 May 21, 120110.|Animal Diseases. 02 November 2021.|bioRxiv. 2024 Feb 9.|Nat Commun. 2022 Mar 2;13(1):1116.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, sealed storage, away from moisture and light)
• Clinical Information: Launched